The project will increase drug production capacity and integrate advanced technologies across operations to strengthen Amgen’s U.S. supply chain, according to the company.
The France-based company’s new Lufkin, Texas site will reportedly boost lipid-based excipient production while reinforcing supply chains across North America.
